Further exploration of substrate diversity of the sansanmycin biosynthetic pathway using available halogen-and methyl-phenylalanines led to the generation of diverse sansanmycin derivatives, either at the single C-or N-terminus alone or at both C-and N-termini. The structures of all of these derivatives were determined by MS/MS spectra, and amongst them, the structures of [2-Cl-Phe]-sansanmycin H (1) and [2-Cl-Phe]-sansanmycin A (2) were further identified by NMR. Both the C-terminal derivative 1 and the N-terminal derivative 2 were assayed for their antibacterial activities, and compound 1 exhibited moderate activity against P. aeruginosa and ΔtolC mutant E. coli.
During our previous research for substrate promiscuities of NRPSs, four new sansanmycin analogs bearing para-substituted phenylalanines were generated by a precursor-directed method, with high yields [7] . Motivated by these results and combining the bioactivities of the sansanmycin analogs, we further exploited the substrate flexibility of these NRPSs using commercially available 2, 3-fluoro-, 2-, 3-chloro-, 2-, 3-bromo, and 2-, 3-methylphenylalanines for mining metabolites with diverse structures. Herein, we report the study on the substrate preference of NRPSs, the structural elucidation of the resulting compounds, and the antibacterial activity of chlorinated sansanmycins.
Feeding studies with 2-, 3-fluoro-, 2-, 3-chloro-, 2-, 3-bromo, and 2-, 3-methylphenylalanines resulted in either single incorporation into sansanmycin at either the C-terminus or N-terminus alone or in double incorporations into both the Nand C-termini (Figures 1 and 2) . The structures of all of these derivatives were determined by MS/MS spectra, which showed the same fragment patterns as sansanmycins The quantity analysis results showed that six precursors led to the corresponding derivatives at higher levels than sansanmycin H (Figure 2) . Firstly, over two times more C-terminal derivatives of These results demonstrated that 3-Br-, 3-Cl-and 3-Mephenylalanines mainly incorporated into the C-terminus, whereas smaller steric fluorinated phenylalanines, 2-F-and 3-F-phenylalanine mainly incorporated into the N-terminus ( Figure 2 ).
Given our previous results that [4-Cl-phenylalanine]-sansanmycin H exhibited better antibacterial activity against Staphylococcus aureus, the fermentation with precursor 2-Clphenylalanine was scaled up to 20 L to access enough material for a bioassay. As a result, two compounds, [2-Cl-Phe]-sansanmycin H (1, 6 mg) and [2-Cl-Phe]-sansanmycin A (2, 0.8 mg), were isolated.
[2-Cl-Phe]-sansanmycin H (1) was obtained as a white powder with a molecular weight of 858. ESIMS and ESIMS/MS of 1 showed characteristic isotope patterns of a chlorinated compound and a diagnostic fragment of 658, corresponding to the loss of a Cterminal amino acid, which suggested that the precursor 2-Cl-Phe was incorporated into the C-terminus. In support of this hypothesis, the 1 H NMR spectrum of 1 showed a different aromatic pattern from that of sansanmycin H [6] Compounds 1 and 2 were assayed for their antibacterial activities against P. aeruginosa 11, S. aureus CPCC100051, M. smegmatis CPCC240556, wild-type and ΔtolC mutant E. coli, according to the previous method [7] ( Table 2 ). The results showed that the C-terminal derivative, compound 1, exhibited moderate antibacterial activities against P. aeruginosa and ΔtolC mutant E. coli, but the Nterminal derivative, compound 2, did not. These results suggested that the C-terminal amino acid of sansanmycin might tolerate more modifications than that of the N-terminus. Except for compounds 1 and 2, more than fifteen compounds can be generated by the precursor-directed method. Recently, the crystal structure was published of MraY from Aquifex aeolicus in complex with its naturally occurring inhibitor, muraymycin D2. MraY undergoes remarkably large conformational arrangements near the active site after binding muraymycin D2 [11] . These findings would help us to perform structure-activity relationship research of sansanmycin analogues for more targeted separation and purification. cm, Tosoh Corporation, Tokyo, Japan) were used for column chromatography. HPLC analysis and separation were performed on a Shimadzu DGU-20A (Shimadzu Corporation, Kyoto, Japan) system. A C18 analysis HPLC column (Waters; 4.6 × 150 mm, 3.5 μm) and a preparative HPLC column (YMC-Pack ODS-A; 250 × 20 mm, 5 μm) were used. 1 H and 13 C NMR spectra were obtained using a Varian Mercury (600 and 150 MHz) spectrometer.
Biological material: The sample of Streptomyces sp. SS was isolated from a soil sample obtained from Guizhou Province of China, produced a series of sansanmycins. The nucleotide sequencing of Streptomyces sp. SS containing the biosynthetic gene cluster for sansanmycins has been completed [12] . The identification of the biosynthetic gene cluster of sansanmycins may provide further insight into biosynthetic mechanisms for uridyl peptide antibiotics. Antibacterial activity assay: Antibacterial activity was evaluated by the previous method [7] . Five bacterial strains, P. aeruginosa 11, S. aureus CPCC100051, M. smegmatis CPCC240556, wild-type and ΔtolC mutant E. coli were used. 1 H NMR spectrum of compound 2.
